NCT00253188View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

653

Participants

Timeline

Start Date

February 28, 1997

Study Completion Date

December 31, 1998

Conditions

Alzheimer DiseaseDementia

Interventions

DRUG

galantamine hydrobromide

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY